Updated time: 2021-05-25 13:48:52
33T-1100511
2021-05-25
know-how
We generated several mouse monoclonal antibodies against SARS-CoV-2 nucleoprotein (NP), and developed a COVID-19 antigen rapid test. The COVID-19 antigen rapid test has completed all required TFDA EUA testing. Clinical data showed 100% sensitivity, 100 % specificity and 100% accuracy. The rapid test shows excellent sensitivity for detecting wild-type as well as SARS-CoV-2 variants (UK B.1.1.7and US B.1.2). It does not cross-react with pathogens that cause human respiratory syndrome which includes 12 viruses and 10 bacteria. Finally, this rapid test shows high sensitivity, specificity and stability.
- The COVID-19 antigen rapid test has completed all required TFDA EUA testing.
- Clinical data showed 100% sensitivity, 100 % specificity and 100% accuracy.
- The test can detect SARS-CoV-2 UK variant (B.1.1.7).
- The high sensitivity and specificity of COVID-19 antigen rapid test has been verified by third-party certification.
- Monoclonal antibodies against SARS-CoV-2 nucleoprotein
- SARS-CoV-2 detection
Han-Chung Wu, Wan-Yu Chen, Shih-Han Ko
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

COVID-19 antigen rapid test